Exercise-Induced Bronchospasm Clinical Trial
Official title:
Effects of Montelukast on Occult Exercise-Induced Bronchospasm in Athletes
The purpose of this study is to determine if treatment of exercise-induced Bronchospasm with montelukast will help college athletes train more effectively and thus become more competitive in a non ergogenic manner.
Exercise-Induced Bronchospasm (EIB) affects between 7-30% of highly trained athletes. The first phase of this study is to screen varsity level college athletes for EIB using Eucapnic hyperventilation (EVH). Those athletes who screen positive, will be enrolled in phase two, a randomized double-blinded placebo controlled double crossover study. At enrollment, athletes will undergo a cardiopulmonary stress test (CPST) and induced sputum sampling and will then be prescribed daily montelukast/placebo for a three week period. Athletes will return after three weeks and repeat the EVH, CPST, and induced sputum. They will then have a one week washout period followed by crossover once again to daily montelukast/placebo for another three weeks. After the second three weeks they will once again return for a final EVH, CPST, and induced sputum. The goal of this study is to demonstrate that effectively blunting the EIB response with montelukast, indices of ventilation,exercise tolerance, and perhaps overall physical fitness improve, allowing athletes to train more effectively, in a nonergogenic manner. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00085774 -
Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma
|
Phase 3 | |
Withdrawn |
NCT03610932 -
Vitamin C & Exercise Induced Bronchoconstriction (EIB)
|
N/A | |
Completed |
NCT00268723 -
Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB
|
Phase 3 | |
Withdrawn |
NCT00662779 -
Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)
|
Phase 3 | |
Completed |
NCT00701025 -
Mechanisms of Exercise-induced Bronchospasm
|